Telix Pharmaceuticals (TLX) Current Leases (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Current Leases for 3 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 239.89% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, up 239.89% year-over-year, with the annual reading at $5.5 million for FY2025, 258.86% up from the prior year.
  • Current Leases for Q4 2025 was $5.5 million at Telix Pharmaceuticals, up from $1.6 million in the prior quarter.
  • The five-year high for Current Leases was $5.5 million in Q4 2025, with the low at $387339.3 in Q4 2023.
  • Average Current Leases over 3 years is $2.5 million, with a median of $1.6 million recorded in 2024.
  • The sharpest move saw Current Leases skyrocketed 321.41% in 2024, then skyrocketed 239.89% in 2025.
  • Over 3 years, Current Leases stood at $387339.3 in 2023, then surged by 321.41% to $1.6 million in 2024, then surged by 239.89% to $5.5 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $5.5 million, $1.6 million, and $387339.3 for Q4 2025, Q4 2024, and Q4 2023 respectively.